What it's for (Indications)
- Cholecalciferol (Vitamin D3) is indicated for the prevention and treatment of vitamin D deficiency.
- This includes populations at high risk of deficiency, such as the elderly, individuals with limited sun exposure, those with malabsorption syndromes (e.
- g.
- , celiac disease, inflammatory bowel disease, cystic fibrosis, bariatric surgery), and patients on certain medications known to affect vitamin D metabolism (e.
- g.
- , anticonvulsants, glucocorticoids).
- It is also used as an adjunctive therapy in the management of osteoporosis to improve bone mineral density and reduce fracture risk, typically in conjunction with calcium supplementation.
- Furthermore, it plays a crucial role in maintaining proper calcium and phosphate homeostasis, supporting normal bone mineralization, and contributing to overall musculoskeletal and immune function.
- The appropriate indication and dosage must be determined by a healthcare professional based on individual patient assessment, including serum 25-hydroxyvitamin D levels and clinical risk factors for deficiency or related conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cholecalciferol must be individualized based on the patient's age, serum 25-hydroxyvitamin D levels, calcium and phosphate status, and underlying medical conditions. For the prevention of vitamin D deficiency, typical daily recommendations range from 600 to 1000 International Units (IU) for adults, though higher doses may be required for specific populations or during certain periods. For the treatment of established vitamin D deficiency, therapeutic doses can range from 1000 IU to 50,000 IU daily, weekly, or monthly, depending on the severity of the deficiency and the healthcare provider's clinical judgment. In cases of severe deficiency (e.g., 25-hydroxyvitamin D levels < 12 ng/mL), loading doses of up to 50,000 IU once weekly for 6-8 weeks, followed by maintenance therapy, are common. It is crucial to monitor serum 25-hydroxyvitamin D, calcium, and parathyroid hormone levels during therapy to ensure efficacy and prevent toxicity. Self-medication with high doses without professional guidance is strongly discouraged due to potential risks. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated at recommended doses, cholecalciferol can cause side effects, primarily associated with hypervitaminosis D or hypercalcemia resulting from excessive intake.
- Common side effects, especially with supratherapeutic doses, include nausea, vomiting, constipation, abdominal pain, loss of appetite, metallic taste, and dry mouth.
- More serious adverse effects are related to hypercalcemia and can manifest as polyuria (increased urination), polydipsia (increased thirst), weakness, fatigue, headache, dizziness, muscle pain, and joint pain.
- Chronic hypercalcemia can lead to nephrocalcinosis (calcium deposits in the kidneys), nephrolithiasis (kidney stones), irreversible kidney damage, and cardiovascular complications, including arrhythmias and hypertension.
- In severe cases, acute hypercalcemia can be life-threatening.
- Patients should be educated on the symptoms of hypercalcemia and advised to seek medical attention if they experience any such symptoms.
Serious Warnings
- Black Box Warning: Serious Warnings: While Cholecalciferol (Vitamin D3) does not typically carry a formal FDA Black Box Warning, it is imperative to acknowledge the significant risks associated with its misuse or excessive intake, primarily hypercalcemia and hypervitaminosis D. These conditions can lead to severe and potentially life-threatening consequences. Overdosing can result in dangerously high serum calcium levels, manifesting as severe nausea, vomiting, constipation, polyuria, polydipsia, dehydration, muscle weakness, and confusion. Chronic hypercalcemia can lead to irreversible renal damage (nephrocalcinosis, nephrolithiasis), cardiovascular abnormalities (e.g., cardiac arrhythmias, vascular calcification), and soft tissue calcification, significantly impairing organ function. Patients with pre-existing conditions such as sarcoidosis, kidney disease, or hyperparathyroidism, or those on certain medications like thiazide diuretics or cardiac glycosides, are particularly vulnerable to vitamin D toxicity and hypercalcemia. Healthcare providers must ensure regular monitoring of serum calcium, urinary calcium, and 25-hydroxyvitamin D levels, especially during high-dose therapy or in susceptible populations, to mitigate these serious risks. Patients should be thoroughly counseled on the importance of adhering to prescribed dosages and recognizing symptoms of toxicity to prevent severe adverse outcomes.
- Patients receiving cholecalciferol therapy require careful monitoring, particularly those receiving high doses or with pre-existing conditions.
- Serum calcium levels, urinary calcium excretion, and serum 25-hydroxyvitamin D concentrations should be regularly assessed to prevent hypercalcemia and vitamin D toxicity.
- Caution is advised in patients with impaired renal function, as they may have altered vitamin D metabolism and an increased risk of hypercalcemia.
- Patients with sarcoidosis or other granulomatous diseases may exhibit increased sensitivity to vitamin D and hypercalcemia due to extrarenal production of 1,25-dihydroxyvitamin D; these individuals require close monitoring.
- Concomitant use of thiazide diuretics may increase the risk of hypercalcemia, while corticosteroids can decrease vitamin D efficacy.
- Patients taking cardiac glycosides (e.
- g.
- , digoxin) should be monitored carefully, as hypercalcemia can potentiate the effects of these drugs, increasing the risk of arrhythmias.
- Regular assessment of bone mineral density may also be warranted in patients receiving long-term treatment for osteoporosis.
How it Works (Mechanism of Action)
Cholecalciferol, also known as Vitamin D3, is a fat-soluble secosteroid that plays a crucial role in calcium and phosphate homeostasis. Upon ingestion or synthesis in the skin via ultraviolet B (UVB) radiation, cholecalciferol is transported to the liver, where it undergoes 25-hydroxylation to form 25-hydroxyvitamin D [25(OH)D], also known as calcifediol. This is the main circulating form of vitamin D, used to assess vitamin D status. Subsequently, 25(OH)D is further hydroxylated in the kidneys by 1-alpha-hydroxylase to form 1,25-dihydroxyvitamin D [1,25(OH)2D], calcitriol, which is the biologically active form. Calcitriol binds to the vitamin D receptor (VDR) present in various target tissues, including the intestines, kidneys, and bones. This binding initiates a cascade of genomic and non-genomic effects, primarily promoting intestinal absorption of calcium and phosphate, facilitating renal reabsorption of these minerals, and regulating bone remodeling processes. This intricate mechanism ensures adequate calcium and phosphate levels for proper bone mineralization, neuromuscular function, and cellular processes throughout the body.
Commercial Brands (Alternatives)
No other brands found for this formula.